$PBIO is at a tipping point. Demand grew modestly through its early years, but is expected to accelerate starting in 2020. After a decade of marketing its original PCT sample preparation platform to academic opinion leaders and early research customers, the Company recently launched two new proprietary technology platforms opening major new market opportunities. In our view, the overall story is solid, and the combination of new platform products, new commercial applications, and customers positions PBIO squarely to move its business to the next level. https://s1.q4cdn.com/460208960/files/News/201..._Senko.pdf